BOSTON, March 16 /PRNewswire/ -- PAREXEL experts will address the benefits of rigorous early phase clinical development at the 110th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), to be held at the Gaylord National Resort in National Harbor, Maryland from March 18 - 21, 2009. The focus of PAREXEL’s presence at the ASCPT meeting will be to help biopharmaceutical companies understand best practice approaches for identifying and selecting the most promising new compounds earlier.
During the meeting, Klaus Franke, M.D., Clinical Research Physician, Early Phase, PAREXEL will present the poster “A Study to Validate a Capsaicin Model of Experimental Pain in Healthy Human Volunteers,” co-authored with PAREXEL colleagues Matthias Grossmann, M.D., Ph.D., Vice President, Early Phase Consulting Services; Edward Neuhoff, Neurophysiologist; and Dawie Wessels, Senior Director and Early Phase Unit Head. Dr. Franke will address the use of pain modeling in early development and advantages of combining traditional pharmacodynamic methods with relevant neuroscience biomarkers to achieve the goal of alleviating pain and related symptoms. Dr. Franke will discuss how this approach to enhance exploration of safety and efficacy and pharmacokinetic analysis can be applied to a broad range of psychiatry, neuropsychopharmacology, neuroimaging, and neurophysiology clinical studies to provide greater information about Central Nervous System (CNS) treatments. The presentation will be given during Poster Session II, starting at 8:00 a.m. on Friday, March 20.
PAREXEL Early Phase experts will be available at Booth 111 in the exhibit hall to discuss how the Company’s fully integrated First in Man through Proof of Concept services can help biopharmaceutical companies generate better and faster go/no go decisions about their compounds and return solid, reproducible outcomes to succeed in later-phase trials. PAREXEL experts will provide information about PAREXEL’s Early Phase capabilities including early efficacy studies, specialized trial design, rapid recruitment approaches, state-of-the-art technologies, hospital-based resources, and scientific expertise as well as vast experience in the CNS, cardiovascular, respiratory and metabolism/endocrine therapeutic areas. PAREXEL Early Phase experts will also discuss specialized techniques such as Asian ethno-bridging studies, which facilitate Asian trials and the inclusion of Asian countries in global trials.
PAREXEL has conducted more than 1,200 early phase trials over the last five years. The Company’s Early Phase Units have approximately 600 beds--among the largest capacities worldwide--and its bioanalytical laboratory has access to over 500 assay methods. With locations across three continents, PAREXEL Early Phase capabilities provide rapid study-start up and access to diverse patient populations in addition to healthy volunteers. For more information about PAREXEL’s Early Phase capabilities visit: http://www.parexel.com/early_phase.html.
More information about the ASCPT meeting can be found at http://www.ascpt.org/annualmeeting2009.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 51 countries around the world, and has over 9,250 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2008 as filed with the SEC on February 9, 2009, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.
CONTACT: Jennifer Baird, Senior Director of Public Relations of PAREXEL
International, +1-781-434-4409, Jennifer.Baird@PAREXEL.com; or Rebecca
Passo of SHIFT Communications, +1-617-779-1817, rpasso@shiftcomm.com, for
PAREXEL International
Web site: http://www.parexel.com/
